The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer
Phase 2
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000009746
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency ) 2) Active infections 3) Active simultaneous cancer 4)Massive pleural or pericardial effusion 5) Concurrent treatment with steroids or immunosuppressing agent 6) Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunological monitoring
- Secondary Outcome Measures
Name Time Method Anti-tumor effect Disease-free survival Overall survival Safety